|
|
UNITED STATES |
|
|
|
SECURITIES AND EXCHANGE COMMISSION |
|
|
|
Washington, D.C. 20549 |
|
|
|
SCHEDULE 13G/A |
|
Under
the Securities Exchange Act of 1934
(Amendment No. 3)*
Regeneron Pharmaceuticals Incorporated
(Name of Issuer)
COMMON STOCK, $.001 PAR VALUE
(Title of Class of Securities)
75886F 10 7
(CUSIP Number)
December 31, 2006
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
|
o |
Rule 13d-1(b) |
|
o |
Rule 13d-1(c) |
|
x |
Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
CUSIP No. 75886F 10 7 |
|||||
|
|
|||||
|
|
1. |
Names of Reporting
Persons. I.R.S. Identification Nos. of above persons (entities only)
Not applicable |
|||
|
|
|||||
|
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|||
|
|
|
(a) |
o |
||
|
|
|
(b) |
o |
||
|
|
|||||
|
|
3. |
SEC Use Only |
|||
|
|
|||||
|
|
4. |
Citizenship or Place of
Organization |
|||
|
|
|
|
|||
|
Number of |
5. |
Sole Voting Power |
|||
|
|
|||||
|
6. |
Shared Voting Power
|
||||
|
|
|||||
|
7. |
Sole Dispositive Power
|
||||
|
|
|||||
|
8. |
Shared Dispositive Power |
||||
|
|
|||||
|
|
9. |
Aggregate Amount
Beneficially Owned by Each Reporting Person |
|||
|
|
|||||
|
|
10. |
Check if the Aggregate
Amount in Row (9) Excludes Certain Shares (See Instructions) o |
|||
|
|
|||||
|
|
11. |
Percent of Class
Represented by Amount in Row (9) |
|||
|
|
|||||
|
|
12. |
Type of Reporting Person
(See Instructions) |
|||
2
|
Item 1. |
|||
|
|
(a) |
Name of Issuer |
|
|
|
(b) |
Address of Issuer’s
Principal Executive Offices |
|
|
|
|||
|
Item 2. |
|||
|
|
(a) |
Name of Person Filing (ii) Aventis Pharmaceuticals Inc (iii) Aventis Holdings Inc. (iv) Aventis Inc. |
|
|
|
(b) |
Address of Principal
Business Office or, if none, Residence
(ii) 55 Corporate Drive, Bridgewater, New Jersey 08807
(iii) 3711 Kennett Pike, Suite 200 Greenville, Delaware 19801
(iv) 3711 Kennett Pike, Suite 200, Greenville, Delaware 19801 |
|
|
|
(c) |
Citizenship (ii) Aventis Pharmaceuticals Inc : Delaware (iii) Aventis Holdings Inc.: Delaware (iv) Aventis Inc. : Pennsylvania |
|
|
|
(d) |
Title of Class of
Securities |
|
|
|
(e) |
CUSIP Number |
|
|
|
|||
|
Item 3. |
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
||
|
|
(a) |
o |
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). |
|
|
(b) |
o |
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). |
|
|
(c) |
o |
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). |
|
|
(d) |
o |
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). |
|
|
(e) |
o |
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); |
|
|
(f) |
o |
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); |
|
|
(g) |
o |
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); |
|
|
(h) |
o |
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
|
|
(i) |
o |
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); |
|
|
(j) |
o |
Group, in accordance with §240.13d-1(b)(1)(ii)(J). |
|
Item 3 is not applicable. |
|||
3
|
Item 4. |
Ownership |
||
|
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. |
|||
|
|
(a) |
Amount beneficially owned: (i) Sanofi-Aventis : 2,799,552 (ii) Aventis Pharmaceuticals Inc : 2,799,552 (iii) Aventis Holdings Inc.: 2,799,552 (iv) Aventis Inc. : 2,799,552 |
|
|
|
(b) |
Percent of class: (i) Sanofi-Aventis : Under 5.0% (ii) Aventis Pharmaceuticals Inc : Under 5.0% (iii) Aventis Holdings Inc.: Under 5.0% (iv) Aventis Inc. : Under 5.0% |
|
|
|
(c) |
Number of shares as to which the person has:
|
|
|
|
|
(i) |
Sole power to vote or to direct the vote (i) Sanofi-Aventis : 2,799,552 (ii) Aventis Pharmaceuticals Inc : 2,799,552 (iii) Aventis Holdings Inc.: 2,799,552 (iv) Aventis Inc. : 2,799,552 |
|
|
|
(ii) |
Shared power to vote or to direct the vote None |
|
|
|
(iii) |
Sole power to dispose or to direct the disposition of (i) Sanofi-Aventis : 2,799,552 (ii) Aventis Pharmaceuticals Inc : 2,799,552 (iii) Aventis Holdings Inc.: 2,799,552 (iv) Aventis Inc. : 2,799,552 |
|
|
|
(iv) |
Shared power to dispose or to direct the disposition of None |
|
|
|||
|
Item 5. |
Ownership of Five Percent or Less of a Class |
||
|
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x. |
|||
|
|
|||
|
Item 6. |
Ownership of More than Five Percent on Behalf of Another Person |
||
|
Item 6 is not applicable. |
|||
|
|
|||
|
Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person |
||
|
Item 7 is not applicable. |
|||
|
|
|||
|
Item 8. |
Identification and Classification of Members of the Group |
||
|
Item 8 is not applicable. |
|||
|
|
|||
|
Item 9. |
Notice of Dissolution of Group |
||
|
Item 9 is not applicable. |
|||
|
|
|||
|
Item 10. |
Certification |
||
|
Item 10 is not applicable. |
|||
4
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the
information set forth in this statement is true, complete and correct.
|
|
SANOFI-AVENTIS |
||||
|
|
|
|
|||
|
Date: February 13, 2007 |
|
By: |
/s/ Jean-Claude Leroy |
|
|
|
|
|
|
|||
|
|
|
|
|||
|
|
|
|
Jean-Claude LEROY |
||
|
|
|
|
Executive Vice President |
||
|
|
|
|
Chief Financial Officer |
||
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
AVENTIS PHARMACEUTICALS |
|||
|
|
|
INC. |
||
|
|
|
|
||
|
|
|
|
||
|
Date: February 13, 2007 |
|
By: |
/s/ John M. Spinnato |
|
|
|
|
John M. SPINNATO |
||
|
|
|
Vice President and General Counsel |
||
|
|
|
- Pharmaceutical Operations |
||
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
AVENTIS HOLDINGS INC. |
|||
|
|
|
|
||
|
|
|
|
||
|
Date: February 13, 2007 |
|
By: |
/s/ Kathleen A. Winter |
|
|
|
|
Kathleen A. WINTER |
||
|
|
|
President |
||
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
AVENTIS INC. |
|
|
|||
|
|
|
|
||||
|
|
|
|
||||
|
Date: February 13, 2007 |
|
By: |
/s/ Kathleen A. Winter |
|
||
|
|
|
Kathleen A. WINTER |
||||
|
|
|
President |
||||
5